First eviQ broad indication tumour-agnostic immunotherapy protocol published

Following the 1 March 2026 Pharmaceutical Benefits System (PBS) updated listings for ipilimumab and nivolumab for the treatment of immunotherapy sensitive, advanced or metastatic cancers, eviQ has published its first broad indication tumour-agnostic immunotherapy protocol.

This generic protocol has been developed specifically to support health professionals in prescribing and administering ipilimumab and/or nivolumab in accordance with the PBS reimbursed tumour-agnostic indication. It differs from the standard eviQ protocol template. 

ID 4660: Tumour-agnostic advanced or metastatic ipilimumab and/or nivolumab

Read more about this new protocol in their FAQs.